Valuation: Unicycive Therapeutics, Inc.

Market Cap 143M 125M 115M 107M 203M 13.65B 206M 1.38B 538M 6.7B 537M 526M 23.23B P/E 2026 *
-3.79x
P/E 2027 * 1.04x
Enterprise Value 143M 125M 115M 107M 203M 13.65B 206M 1.38B 538M 6.7B 537M 526M 23.23B EV / Sales 2026 *
33.9x
EV / Sales 2027 * 0.48x
Free-Float
97.64%
Yield 2026 *
77.8%
Yield 2027 * 43.5%
1 day-6.46%
1 week-30.39%
Current month+14.29%
1 month-22.54%
3 months-19.03%
6 months-5.13%
Current year-7.11%
1 week 4.45
Extreme 4.45
5.93
1 month 3.93
Extreme 3.93
8.56
Current year 3.93
Extreme 3.93
8.74
1 year 3.71
Extreme 3.71
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
87.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap.
14/05Free

Chief Operating Officer

169,500 0.6716%
14/05Free

Chief Financial Officer

169,500 0.6716%
14/05Free

Director

126,300 0.5004%
Change 5-day change 1-year change 3-year change Capi.($)
-6.46%-30.39%+16.52%-53.79% 143M
-0.07%+0.15%+74.42%+133.37% 57.73B
-0.93%-2.54%+73.64%+93.71% 54.69B
-3.71%-0.35%-14.61%-11.19% 23.75B
-0.05%+6.49%+14.05%+451.36% 24.18B
-2.70%+6.30%+46.83%-2.70% 19.82B
+2.85%+4.54%+43.46%-27.01% 17.14B
+3.58%+13.78%+196.41%+348.55% 16.75B
-1.81%+17.84%+45.86% - 15.57B
-0.57%+2.30%+20.33%+187.27% 13.96B
Average -0.98%+2.18%+51.69%+124.40% 24.37B
Weighted average by Cap. -0.51%+4.13%+58.59%+137.63%

Financials

2026 *2027 *
Net sales 4.23M 3.7M 3.41M 3.17M 6.01M 403M 6.09M 40.82M 15.89M 198M 15.87M 15.53M 686M 300M 263M 242M 225M 427M 28.64B 433M 2.9B 1.13B 14.06B 1.13B 1.1B 48.75B
Net income -40.34M -35.33M -32.54M -30.2M -57.35M -3.85B -58.13M -389M -152M -1.89B -151M -148M -6.55B 186M 163M 150M 139M 265M 17.76B 268M 1.8B 700M 8.72B 699M 684M 30.23B
Net Debt - -
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
06/07/26 USD 5.360 -6.46% 2,094,523
02/07/26 USD 5.730 +8.52% 2,993,015
01/07/26 USD 5.280 +12.58% 6,057,842
30/06/26 USD 4.690 -39.09% 20,126,082
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.360USD
Average target price
39.54USD
Spread / Average Target
+637.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UNCY Stock